This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Examining the 2-Year Data of Abbvie and RegenexBio's ABBV-RGX-314 gene therapy for patients with Non-Proliferative Diabetic Retinopathy
Ticker(s): RGNX, ABBVWho's the expert?
Institution: Cumberland Valley Retina Consultants
- Board-Certified Ophthalmologist and Retina Specialist with fellowship training in Medical Retina
- Currently manages 800 patients with geographic atrophy and 200 patients monthly with diabetic retinopathy. Specializes in evaluating and treating all disorders of the retina and macula including uveitis and innovative treatments for AMD and diabetic retinopathy
- Specializes in diseases of the retina and macula including age-related macular degeneration, diabetic retinopathy, retinal vascular disorders, and uveitis; actively involved in clinical research and participation in retina clinical trials, with peer-reviewed publications and presentations at international ophthalmology meetings, contributing to advancing therapeutic approaches in retinal disease
Interview GoalThis interview will focus on the standard of care and potential of ABBV-RGX-314 in treating non-proliferative diabetic retinopathy.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
